Literature DB >> 24145082

Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells.

Mariola Dorecka1, Krzysztof Siemianowicz, Tomasz Francuz, Wojciech Garczorz, Agnieszka Chyra, Agnieszka Klych, Wanda Romaniuk.   

Abstract

BACKGROUND: Advanced glycation end products (AGEs) take part in the development of diabetic retinopathy. Hyperglycemia triggers an inflammatory response in the retina. These mechanisms may lead to an enhanced expression of adhesion molecules (ICAM-1 and VCAM-1) in human retinal pigment epithelium (HRPE). Glucagon-like peptide 1 (GLP-1) functions as an incretin hormone with antidiabetogenic properties. GLP-1 also possesses vasoprotective properties.
METHODS: The aim of our study was to evaluate the influence of glycated albumin (GlyAlb; 100; 500 and 1000 mg/l) and pro-inflammatory cytokine, TNF-α (2.5 and 10 ng/ml), on expression of RAGE, ICAM-1 and VCAM-1 and to evaluate the influence of GLP-1 (100 nM) and its analogue, exendin-4 (10 nM), on the expression of RAGE, ICAM-1 and VCAM-1 in stimulated HRPE.
RESULTS: TNF-α increased RAGE expression in HRPE cells. The addition of GlyAlb (500 and 1000 mg/l) resulted in a decrease of RAGE expression. Both TNF-α and GlyAlb increased the secretion of both adhesion molecules. In cells co-treated with GLP-1 or exendin-4 both incretins decreased RAGE expression in TNF-α treated cells, and in GlyAlb group. The ICAM-1 expression was lowered by exendin-4 and GLP-1 in cells stimulated by TNF-α and GlyAlb. The similar results were obtained for VCAM-1. All observed alterations were statistically significant.
CONCLUSIONS: The obtained results indicate that both GLP-1 and exendin-4 by decreasing the expression of RAGE in HRPE can make these cells more resistant to circulating AGEs, and decreased expression of circulating VCAM-1 and ICAM-1, can be the result of anti-inflammatory properties of incretins and decreased expression of RAGE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145082     DOI: 10.1016/s1734-1140(13)71069-7

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  10 in total

1.  Local administration of high-dose diabetes medicine exendin-4 inhibits orthodontic tooth movement in mice.

Authors:  Wei-Ren Shen; Hideki Kitaura; Jiawei Qi; Saika Ogawa; Fumitoshi Ohori; Takahiro Noguchi; Aseel Marahleh; Yasuhiko Nara; Pramusita Adya; Itaru Mizoguchi
Journal:  Angle Orthod       Date:  2021-01-01       Impact factor: 2.079

Review 2.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

3.  Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK.

Authors:  Jinmi Lee; Seok Woo Hong; Se Eun Park; Eun Jung Rhee; Cheol Young Park; Ki Won Oh; Sung Woo Park; Won Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-07-02

Review 4.  Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.

Authors:  Sho-ichi Yamagishi; Kei Fukami; Takanori Matsui
Journal:  Cardiovasc Diabetol       Date:  2015-01-13       Impact factor: 9.951

5.  Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells.

Authors:  Juan Li; Lin Chen; Ping Yu; Bin Liu; Jiang Zhu; Ye Yang
Journal:  Molecules       Date:  2014-03-05       Impact factor: 4.411

Review 6.  Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.

Authors:  Michael A Nauck; Daniel R Quast
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

Review 7.  GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Authors:  Michael A Nauck; Daniel R Quast; Jakob Wefers; Juris J Meier
Journal:  Mol Metab       Date:  2020-10-14       Impact factor: 7.422

Review 8.  Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice.

Authors:  Etelka Pöstyéni; Alma Ganczer; Andrea Kovács-Valasek; Robert Gabriel
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 9.  EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

Authors:  Simona Amodeo; Luigi Mirarchi; Aurelio Seidita; Roberto Citarrella; Anna Licata; Maurizio Soresi; Juan Lucio Iovanna; Lydia Giannitrapani
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

Review 10.  Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.

Authors:  Young-Sun Lee; Hee-Sook Jun
Journal:  Mediators Inflamm       Date:  2016-03-24       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.